NCT07916129Enrolling by invitation
Single-center Transformational Study on Feasibility and Efficacy of Respiratory Motion Management Using Novel Position Fixation Device for Lung Cancer Patients Undergoing Stereotactic Body Radiation Therapy(2023 No.358 Project)
Source: ClinicalTrials.gov · Last updated 4 Nov 2026
Brief summary (registry, in English)
This single-center study evaluates a novel body position and breath-holding device for lung cancer patients receiving stereotactic body radiation therapy. We will enroll 50 patients with single peripheral non-small cell lung cancer, compare tumor movement and radiation dose distribution with and without the device, to test if the device is safe, feasible and can improve treatment accuracy.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 19 Oct 2026
- Start date
- 10 Sept 2025
- Primary completion date
- 31 Jul 2028
- Lead sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Diseases
- Lung cancer
- NCT number
- NCT07916129
What you commit to
- Study type: Interventional
- Planned participants: 50
- From 10 Sept 2025 to the primary completion date, 31 Jul 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Intolerant or unwilling to receive the integrated respiratory suppression and positioning immobilization device for radiotherapy localization.
Other illness
- Patients with central or ultra-central lung cancer.
Other
- Currently participating or planning to participate in other clinical trials.
- Refuse or be unable to sign the informed consent form for this trial.
- Patients planned to receive SBRT for multiple pulmonary lesions.
- Patients assessed by the investigators of this trial as unsuitable for SBRT treatment.
Who the study is looking for
- Voluntarily participate and sign written informed consent
- Age ≥18 years, gender unlimited
- Clinically diagnosed with single peripheral lung cancer, assessed as suitable for SBRT
- Males or females of childbearing age willing to take contraceptive measures during the trial
- Female of childbearing age must have a negative pregnancy test within 7 days before treatment, and all patients use adequate contraception during treatment and for 4 weeks after
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tianjin Medical University Cancer Institute and Hospital Coordinator of this site? Confirm its status | Tianjin | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.